Skip to main content
Erschienen in: High Blood Pressure & Cardiovascular Prevention 2/2018

01.06.2018 | Review Article

Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies

verfasst von: Marco Pappaccogli, Michele Covella, Elena Berra, Chiara Fulcheri, Silvia Di Monaco, Elisa Perlo, Jacopo Burrello, Silvia Monticone, Denis Rossato, Franco Rabbia, Franco Veglio

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Early uncontrolled studies reported large blood pressure reductions in subjects with resistant hypertension treated with renal denervation, however these results were not confirmed in several of the latest publications.

Aim

The aim of the current study was to evaluate the effectiveness of RDN in controlled studies comparing RDN to either a sham procedure or to medical therapy.

Method

Only controlled studies were included in the analysis. Both the unadjusted and control-adjusted BP changes were calculated.

Results

We identified 11 publications of which only 3 were double-blinded RCTs with a sham control, while 8 were open label studies where the control group was treated with medical therapy. Only 2 studies assessed adherence to medical therapy with robust methodologies. Office BP reduction (− 18/8 mmHg) significantly overestimated ABPM change (− 9/− 5 mmHg), with high heterogeneity between the included studies. When the treatment effect was adjusted for the BP change in the control group, BP changes became non significant (ABPM: − 1.8 for systolic BP [95% CI − 4.5 to 0.9] and − 0.6 for diastolic BP [95% CI − 2.3 to 1.2]). These results were confirmed when only the sham-controlled studies were analysed.

Conclusions

In spite of promising results in early reports, renal denervation fails to show superiority to a sham procedure or to medical therapy in recently published controlled studies. Lack of a sham control in most publications and heterogeneity in assessment of treatment adherence may account for part the variability reported in the studies.

Graphical abstract

Renal denervation fails to show superiority to a sham procedure or to medical therapy in recently published controlled studies.
Literatur
1.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23:3–16.CrossRefPubMed Mancia G, Fagard R, Narkiewicz K, Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23:3–16.CrossRefPubMed
2.
Zurück zum Zitat Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014;63(18):1924–5.CrossRefPubMed Bakris G, Nathan S. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014;63(18):1924–5.CrossRefPubMed
3.
Zurück zum Zitat Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380(9841):591–600.CrossRefPubMed Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380(9841):591–600.CrossRefPubMed
4.
Zurück zum Zitat Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet Lond Engl. 2009;373:1275–81.CrossRef Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet Lond Engl. 2009;373:1275–81.CrossRef
5.
Zurück zum Zitat Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet Lond Engl. 2010;376:1903–9.CrossRef Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet Lond Engl. 2010;376:1903–9.CrossRef
6.
Zurück zum Zitat Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62(3):526–32.CrossRefPubMed Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62(3):526–32.CrossRefPubMed
7.
Zurück zum Zitat Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.CrossRefPubMed Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.CrossRefPubMed
8.
Zurück zum Zitat Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure results from SYMPLICITY HT. J Am Coll Cardiol. 2014;64(11):1071–8.CrossRefPubMed Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure results from SYMPLICITY HT. J Am Coll Cardiol. 2014;64(11):1071–8.CrossRefPubMed
9.
Zurück zum Zitat Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63(5):991–9.CrossRefPubMed Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63(5):991–9.CrossRefPubMed
10.
Zurück zum Zitat Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65(2):407–13.CrossRefPubMed Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65(2):407–13.CrossRefPubMed
11.
Zurück zum Zitat Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202–8.CrossRefPubMed Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202–8.CrossRefPubMed
12.
Zurück zum Zitat Kario K, Ogawa H, Okumura K, SYMPLICITY HTN-Japan Investigators, et al. SYMPLICITY HTN-Japan—first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015;79(6):1222–9.CrossRefPubMed Kario K, Ogawa H, Okumura K, SYMPLICITY HTN-Japan Investigators, et al. SYMPLICITY HTN-Japan—first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015;79(6):1222–9.CrossRefPubMed
13.
Zurück zum Zitat Mathiassen ON, Vase H, Bach NJ, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34:1639–47.CrossRefPubMedPubMedCentral Mathiassen ON, Vase H, Bach NJ, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34:1639–47.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–70.CrossRefPubMed Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–70.CrossRefPubMed
15.
Zurück zum Zitat Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study—a randomized controlled trial. J Hypertens. 2016;34:1863–71.CrossRefPubMedPubMedCentral Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study—a randomized controlled trial. J Hypertens. 2016;34:1863–71.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24:263–74.CrossRefPubMed Fadl Elmula FE, Jin Y, Yang WY, et al. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Press. 2015;24:263–74.CrossRefPubMed
17.
Zurück zum Zitat Persu A, Azizi M, Jin Y, et al. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens. 2014;32(12):2422–7.CrossRefPubMed Persu A, Azizi M, Jin Y, et al. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens. 2014;32(12):2422–7.CrossRefPubMed
18.
Zurück zum Zitat Howard JP, Cole GD, Sievert H, et al. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014;172(1):29–35.CrossRefPubMed Howard JP, Cole GD, Sievert H, et al. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol. 2014;172(1):29–35.CrossRefPubMed
19.
Zurück zum Zitat Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trials. Lancet. 2015;385(9981):1957–65.CrossRefPubMed Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trials. Lancet. 2015;385(9981):1957–65.CrossRefPubMed
20.
Zurück zum Zitat Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension—the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21.CrossRefPubMed Bakris GL, Townsend RR, Flack JM, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension—the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21.CrossRefPubMed
21.
Zurück zum Zitat Pancholy SB, Shantha GP, Patel TM, Sobotka PA, Kandzari DE. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. Am J Cardiol. 2014;114(6):856–61.CrossRefPubMed Pancholy SB, Shantha GP, Patel TM, Sobotka PA, Kandzari DE. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. Am J Cardiol. 2014;114(6):856–61.CrossRefPubMed
22.
Zurück zum Zitat Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159–64.CrossRefPubMedPubMedCentral Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159–64.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Vàclavik J, Sediàk R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75.CrossRefPubMed Vàclavik J, Sediàk R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75.CrossRefPubMed
24.
Zurück zum Zitat Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27.CrossRefPubMed Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219–27.CrossRefPubMed
25.
Zurück zum Zitat Mahfoud F, Schmieder RE, Azizi M, et al. Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38(44):3272–81.CrossRefPubMedPubMedCentral Mahfoud F, Schmieder RE, Azizi M, et al. Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38(44):3272–81.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Rabbia F, Fulcheri C, Di Monaco S, et al. Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs. High Blood Press Cardiovasc Prev. 2016;23(4):341–5.CrossRefPubMed Rabbia F, Fulcheri C, Di Monaco S, et al. Adherence to antihypertensive therapy and therapeutic dosage of antihypertensive drugs. High Blood Press Cardiovasc Prev. 2016;23(4):341–5.CrossRefPubMed
28.
Zurück zum Zitat Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl. 2003;21(2):S37–42.CrossRefPubMed Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl. 2003;21(2):S37–42.CrossRefPubMed
29.
Zurück zum Zitat Wenwen C, Chang Y, He L, et al. Effect of renal sympathetic denervation on hepatic glucose metabolism and blood pressure in a rat model of insulin resistance. J Hypertens. 2016;34:2465–74.CrossRef Wenwen C, Chang Y, He L, et al. Effect of renal sympathetic denervation on hepatic glucose metabolism and blood pressure in a rat model of insulin resistance. J Hypertens. 2016;34:2465–74.CrossRef
30.
Zurück zum Zitat Tsioufis C, Dimitriadis K, Kasiakogias A, et al. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. J Hypertens. 2017;35(5):1100–8.CrossRefPubMed Tsioufis C, Dimitriadis K, Kasiakogias A, et al. Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. J Hypertens. 2017;35(5):1100–8.CrossRefPubMed
Metadaten
Titel
Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies
verfasst von
Marco Pappaccogli
Michele Covella
Elena Berra
Chiara Fulcheri
Silvia Di Monaco
Elisa Perlo
Jacopo Burrello
Silvia Monticone
Denis Rossato
Franco Rabbia
Franco Veglio
Publikationsdatum
01.06.2018
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 2/2018
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-018-0260-5

Weitere Artikel der Ausgabe 2/2018

High Blood Pressure & Cardiovascular Prevention 2/2018 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.